Use of Advanced Technology in the Management of Persons With Diabetes Mellitus

Publication Date: May 1, 2021
Last Updated: November 7, 2023

Recommendations

1: What glucose metrics should be used in clinical practice to assess glycemic status?

Q1.1 What are the priority metrics for clinical decision-making regarding the use of diabetes technology?

Established clinical targets should be used to individualize glycemic targets and adjust therapy based on each individual’s overall health status, concomitant medical condition (eg, pregnancy, frailty), and risk for hypoglycemia:
All Persons with Diabetes
  • Number of days of active CGM use: 14 days preferred
  • Percentage of data available from active CGM use: >70% of data from 14 days
  • Mean glucose: Individualized to targets
  • Glucose management indicator (GMI): Individualized to targets
  • Glycemic variability, percent coefficient of variation (%CV [coefficient of variation]): 36%
Type 1 Diabetes (T1D)/Type 2 Diabetes (T2D)
  • Percentage of time in range (%TIR) 70 to 180 mg/dL: >70%
  • Percentage of time below range (%TBR) <70 mg/dl: <4%
  • %TBR <54 mg/dL: <1%
  • Percentage of time above range (%TAR) >180 mg/dL: <25%
  • %TAR >250 mg/dL: <5%
Older/High Risk T1D/T2D
  • %TIR 70 to 180 mg/dL: >50%
  • %TBR 250 mg/dL: 70%: <1%
  • %TBR <54 mg/dL: ~0%
  • %TAR >140 mg/dL: <25%
Pregnancy: T1D
  • %TIR 63 to 140 mg/dL: >70%
  • %TBR <63 mg/dL: <4%
  • %TBR <54 mg/dL: <1%
  • %TBR >140 mg/dL: <25%
(CL-I2)
338943

Overview

Title

Use of Advanced Technology in the Management of Persons With Diabetes Mellitus

Authoring Organization